ICU Medical AI Stock Analysis
ICU Medical (IC7) AI Stock Analysis
ICU Medical
(Frankfurt:IC7)
No summary available
ICU Medical (IC7) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 4.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 40
- Price to Earnings (P/E)
- 74.4
- Beta (1Y)
- 0.53
- Revenue Growth
- -10.78%
- EPS Growth
- ―
- Country
- Germany
- Employees
- 13,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
ICU Medical Business Overview & Revenue Model
Company Description
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion...
ICU Medical Earnings Call Summary
The call was broadly positive. The company reported solid revenue, EBITDA, EPS and free cash flow performance; record results in Infusion Systems and Consumables; improving gross margins; lower integration spending; debt reduction; and guidance toward the high end of its ranges. These strengths outweighed the stated challenges, including Vital Care's decline, logistics disruptions, tariff and FX pressures, ongoing remediation spending and approval timing for certain products.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
ICU Medical expects Consumables to deliver mid-single-digit growth for 2026 and Infusion Systems to be at least high single digits for the full year 2026, while Vital Care will have a larger year-over-year decrease than previously mentioned; full-year adjusted EBITDA is expected towards the higher end of the previously provided guidance range of $415 million to $435 million and adjusted EPS towards the higher end of $8.60 to $9, with no changes to guidance for gross margin rate, operating expenses or interest expense. Full-year CapEx guidance was lowered from $85 million to $75 million, although fourth-quarter CapEx spending is expected to be meaningfully higher than the average quarterly spend to date; year-to-date free cash flow was $173 million versus an original full-year target of $150 million, Q4 free cash flow won't be as strong as Q3, and the company does not expect a material benefit from tariff refunds. The company expects to finish 2026 slightly below 2x net leverage, continue to pay down debt in Q4, and remains focused on achieving a gross margin target of 43% by the time we exit 2027.
ICU Medical Risk Analysis
ICU Medical disclosed 40 risk factors in its most recent earnings report. ICU Medical reported the most risks in the "Production" category.
Latest Risks Added
0 New RisksICU Medical Peers Comparison
Overall Rating
MMSI71Outperform
BDX63Neutral
TFX57Neutral
ANGO52Neutral
BAX46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | $5.19B | 32.20 | 9.65% | ― | 9.34% | 33.77% | |
| 63Neutral | $59.39B | 52.54 | 4.64% | 1.82% | -7.40% | -28.89% | |
| 57Neutral | $6.15B | 18.64 | 9.74% | 0.88% | -29.30% | ― | |
| 52Neutral | $499.19M | -15.03 | -19.25% | ― | 8.20% | -0.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $13.35B | -18.70 | -11.62% | 0.16% | 5.33% | -164.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:IC7 | ICU Medical | 164.00 | 48.00 | 41.38% | |
| ANGO | Angiodynamics, Inc. | 11.78 | -0.10 | -0.84% | |
| BAX | Baxter International Inc | 25.54 | 7.43 | 40.99% | |
| BDX | Becton, Dickinson and Co | 216.47 | 69.01 | 46.80% | |
| MMSI | Merit Medical | 86.35 | 2.18 | 2.59% | |
| TFX | Teleflex | 157.10 | 50.72 | 47.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
